Table 2.
Clearance of senescent cells by various senolytics.
| Senolytic agents | Senolytic targets | Killing senescent cells | Refs |
|---|---|---|---|
| Dasatinib + Quercetin | EFNB, PI3K, P21Cip1, PAI2, Bcl-xl | Pre-adipocytes, HUVECs, MEFs, BM-MSCs | Zhu et al., 2015 |
| ABT-263 | Bcl-2, Bcl-xl, Bcl-w | WI-38, IMR-90, HRECs, MEFs, HUVECs, HSCs, MuSCs | Chang et al., 2016; Zhu et al., 2016 |
| ABT-737 | Bcl-2, Bcl-xl, Bcl-w | IMR-90, MEFs | Yosef et al., 2016 |
| UBX0101 | MDM2-P53 | Chondrocytes | Jeon et al., 2017 |
| FOXO4-DRI | FOXO4-P53 | IMR-90, WI-38, BJ | Baar et al., 2017 |
| 17-DMAG | HSP90-AKT | MEFs, MSCs, IMR-90, WI-38 | Fuhrmann-Stroissnigg et al., 2017 |
| EF24 | Bcl-xl, Mcl-1 | WI-38, IMR-90, HUVECs, HRECs, pre-adipocytes | Li et al., 2019 |
| Piperlongumine (PL) | Oxidation resistance 1 | WI-38 | Wang et al., 2016; Zhang et al., 2018 |
| Fisetin | PI3K/ AKT | HUVECs | Zhu et al., 2017 |
| A1331852, A1155463 | Bcl-xl | HUVECs, IMR-90 | Zhu et al., 2017 |
| 2-deoxy-D-glucose (2-DG) | Glycolysis | CISCs(lymphomas), vascular smooth muscle cells | Dörr et al., 2013; Gardner et al., 2015 |
| Panobinostat (pano) | Histone 3 acetylation, Bcl-xl | CISCs (NSCLC, HNSCC) | Samaraweera et al., 2017 |
| PZ15227 | Bcl-xl, E3 ligase cereblon | WI-38, HREC, pre-adipocytes | He et al., 2020b |
EFNB, ephrin ligand (EFN) B1 and B3; PI3K, phosphatidylinositol-4, 5-bisphosphate 3-kinase; PAI-2, plasminogen-activated inhibitor-2; HSP90, heat shock protein 90; HUVECs, human umbilical vein epithelial cells; MEFs, murine embryonic fibroblasts; BM-MSCs, bone marrow-derived murine mesenchymal stem cells; HRECs, human renal epithelial cells; WI-38, human lung fibroblasts; IMR-90, human lung fibroblasts; HSCs, hematopoietic stem cells; MuSCs, muscle stem cells; BJ, human foreskin fibroblasts; MSCs, murine mesenchymal stem cells; CISCs, chemotherapy-induced senescent cells; NSCLC, non-small cell lung cancer; HNSCC, head and neck squamous cell carcinoma.